Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia
Sponsor: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
A PHASE2 clinical study on B-Cell Chronic Lymphocytic Leukemia (B-CLL), this trial is completed. The trial is conducted by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .